Picture loading failed.

Anti-EGFR therapeutic antibody (Pre-made Panitumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-425-1mg 1mg 3090
GMP-Bios-ab-425-10mg 10mg 21890
GMP-Bios-ab-425-100mg 100mg 148000
GMP-Bios-ab-425-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-EGFR therapeutic antibody (Pre-made Panitumumab biosimilar,Whole mAb)
INN Name Panitumumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5sx5:HL:JK/5sx4:HL:JI
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2004
Year Recommended2005
CompaniesAmgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma
Conditions ApprovedColorectal cancer
Conditions ActiveAnal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer
Conditions DiscontinuedHead and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours
Development TechAbgenix XenoMouse